Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction

NCT04049539 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
Persistent Disease
Refractory Acute Myeloid Leukemia

Interventions

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

Sponsor

Ohio State University Comprehensive Cancer Center